Epithelial ovarian cancer (EOC) represents a heterogeneous spectrum of disease entities at a clinical, pathological and molecular level. Ovarian cancer is the second most lethal gynaecological malignancy worldwide behind cervical cancer and the first in developed countries, with ∼200 000 women dying globally in 2020.1 A study of epidemiological trends from 1990 to 2019 showed that highly developed regions had the highest burden and mortality.2